This study is in progress, not accepting new patients
A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Orange, California and other locations
- Dates
- start:end: about
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- ID
- NCT03764293
- Phase
- Phase 3 Liver Cancer Research Study
- Study Type
- Interventional
- Participants
- About 543 people participating
- Last Updated